CRIS Current Research Information System

GUGLIOTTA, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.253
AS - Asia 4.416
EU - Europa 3.750
SA - Sud America 326
AF - Africa 302
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.060
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.216
SG - Singapore 1.373
CN - Cina 1.311
GB - Regno Unito 1.154
VN - Vietnam 859
IT - Italia 475
SE - Svezia 475
DE - Germania 461
HK - Hong Kong 315
NL - Olanda 293
BR - Brasile 241
IN - India 229
RU - Federazione Russa 217
FR - Francia 139
IE - Irlanda 139
KR - Corea 128
UA - Ucraina 107
ZA - Sudafrica 88
TG - Togo 82
EE - Estonia 72
CI - Costa d'Avorio 56
JP - Giappone 54
BG - Bulgaria 50
JO - Giordania 48
NG - Nigeria 37
FI - Finlandia 35
CH - Svizzera 32
AR - Argentina 31
BE - Belgio 25
AT - Austria 23
CA - Canada 22
ID - Indonesia 22
SC - Seychelles 21
IR - Iran 17
EC - Ecuador 16
PL - Polonia 16
CL - Cile 12
MX - Messico 12
IQ - Iraq 11
AU - Australia 10
TR - Turchia 9
BD - Bangladesh 7
CO - Colombia 7
ES - Italia 7
PY - Paraguay 6
GR - Grecia 5
IL - Israele 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
LB - Libano 4
LT - Lituania 4
MA - Marocco 4
NO - Norvegia 4
PE - Perù 4
PK - Pakistan 4
TN - Tunisia 4
UZ - Uzbekistan 4
VE - Venezuela 4
KE - Kenya 3
MY - Malesia 3
NP - Nepal 3
RO - Romania 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
EG - Egitto 2
LA - Repubblica Popolare Democratica del Laos 2
PT - Portogallo 2
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
GM - Gambi 1
HN - Honduras 1
KW - Kuwait 1
KZ - Kazakistan 1
LC - Santa Lucia 1
LV - Lettonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PH - Filippine 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZM - Zambia 1
Totale 14.060
Salva come PNG Salva come JPEG
Città #
Southend 1.072
Singapore 929
Ashburn 625
Fairfield 606
Chandler 473
Hong Kong 313
Woodbridge 298
Wilmington 295
Houston 287
Hefei 276
Seattle 276
Beijing 233
Dong Ket 226
Cambridge 220
Princeton 201
Ann Arbor 170
Ho Chi Minh City 169
Hanoi 153
Dublin 139
Boardman 133
Seoul 124
Bologna 109
Nanjing 101
Santa Clara 98
Westminster 83
Lomé 82
Padova 71
Berlin 64
Los Angeles 61
New York 61
Abidjan 56
Jinan 50
Sofia 50
Amman 48
Dallas 48
Buffalo 45
Shenyang 43
Milan 42
Redondo Beach 42
Tokyo 42
Jacksonville 38
Abeokuta 37
Changsha 36
Turin 34
Saint Petersburg 33
Bengaluru 31
Bern 27
Helsinki 27
Nanchang 27
San Diego 27
Tianjin 27
Frankfurt am Main 26
São Paulo 26
Medford 25
Brussels 24
Falls Church 24
Redmond 24
Jiaxing 23
Zhengzhou 22
Hebei 21
Munich 21
Des Moines 20
Nuremberg 20
Biên Hòa 19
Bremen 19
Haiphong 19
Shanghai 19
Da Nang 18
Guangzhou 18
Mountain View 18
Norwalk 17
Dearborn 15
Rome 15
Phoenix 14
Warsaw 14
Boston 13
Chengdu 13
Falkenstein 13
Jakarta 13
Ninh Bình 13
Taizhou 13
Haikou 12
Hangzhou 12
London 12
Chicago 11
Ningbo 11
Redwood City 11
Yubileyny 11
Ha Long 10
Hải Dương 10
Stockholm 10
Belo Horizonte 9
Denver 9
Hyderabad 9
Kuban 9
Mülheim 9
Quận Một 9
Tehran 9
Brooklyn 8
Bắc Giang 8
Totale 9.506
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 362
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia 310
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 254
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 230
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 203
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 202
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 200
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 195
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 193
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 192
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 192
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 179
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 177
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 176
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 176
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study 174
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 166
A review of the European LeukemiaNet recommendations for the management of CML 164
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 163
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 162
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 160
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 160
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 158
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 157
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 155
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 151
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 150
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 149
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 147
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 147
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 145
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 143
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 142
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 141
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 138
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 137
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 137
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 136
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 135
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 133
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 132
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 132
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 131
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 131
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 130
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 130
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 129
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 128
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 127
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 126
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 126
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 126
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 126
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 125
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 124
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 124
Diagnosis and classification of the risk 123
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 123
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 121
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 119
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 119
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 118
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 117
Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia 117
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 116
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 115
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib 115
Essential role of lyn in fibrosis 113
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 113
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 110
First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies 109
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 109
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 107
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML 107
Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study 106
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 106
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials 103
Safety profiles of first-line TKIS and managing adverse effects 103
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 102
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 102
NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: BEYOND 4 YEARS RESULTS REMAIN STABLE - THE GIMEMA CML WP TRIAL CML0307 101
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 101
Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study 101
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase 99
Chronic myeloid leukemia. Drug selection in first-line therapy and beyond 96
EARLY PREDICTORS OF PROGRESSION TO ACCELERATED-BLASTIC PHASE IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 95
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 93
Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia patients 93
Current treatment approaches in CML. 89
EUTOS SCORE IS PREDICTIVE FOR SURVIVAL AND OUTCOME IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH NILOTINIB-BASED REGIMENS 89
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 88
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 88
Differences among young adults, adults and elderly chronic myeloid leukemia patients 87
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 87
Thyrosin kinase inhibitors: nilotinib 85
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report 82
null 81
Imatinib in chronic myeloid leukemia elderly patients. 81
null 77
null 76
Totale 13.520
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.951
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.951
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021942 0 0 0 0 0 41 26 108 153 60 150 404
2021/20221.674 153 57 137 140 170 99 27 97 83 103 286 322
2022/20231.961 198 299 107 240 156 140 87 122 341 35 159 77
2023/2024507 27 83 36 55 47 116 25 19 23 32 18 26
2024/20252.352 66 357 205 164 267 106 148 63 32 366 119 459
2025/20263.140 696 667 532 445 569 231 0 0 0 0 0 0
Totale 14.369